Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Savient sues Barr over generic version of Oxandrin
Oxandrin is an oral therapy used to promote weight gain following extensive surgery, chronic infection, or severe trauma. Oxandrin is also indicated for patients who, without definite reason,
Oxandrin is an oral therapy used to promote weight gain following extensive surgery, chronic infection, or severe trauma. Oxandrin is also indicated for patients who, without definite reason,
The waiver makes the license non-exclusive and as a result Barr Laboratories, a subsidiary of Barr Pharmaceuticals, intends to launch its generic version of Ovcon 35 in October
CytRx was awarded the grant by the National Institute of Diabetes and Digestive and Kidney Diseases, a part of the National Institutes of Heath (NIH), based on the
AZD-103 is a small molecule compound in phase I clinical development that has the potential to both reduce disease progression and improve symptoms such as cognitive function in
This approval allows BDSI to continue recruitment at existing investigational sites and initiate new sites in California. The panel had mandated a temporary pause in recruitment pending a
The main objective of the study was to assess the efficacy and safety of the drug. No significant adverse effects were reported. Additionally no treatment-related effects on vital
InterMune is conducting the research in collaboration with Array BioPharma. Upon successful review, InterMune will initiate the phase I clinical program of ITMN-191. Studies of ITMN-191 demonstrated a
Juvaris will develop the vaccine in collaboration with Penn State College of Medicine, Penn State University’s medical school Juvaris’ vaccine technology will be tested in rodent tumor models
The study focused on 5% and 7.5% solutions of AN2690 in onychomycosis, a fungal infection of the nail and nail bed. At six months, halfway through the study,
This trial is designed to evaluate the safety and tolerability of MacuSight’s proprietary formulation of sirolimus when administered in various doses through two different types of ocular injections.